Relapsed/Refractory AML Clinical Trial
Official title:
CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia
The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04623944 -
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
|
Phase 1 | |
| Completed |
NCT01258816 -
The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
|
Phase 1 | |
| Terminated |
NCT02520427 -
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
|
Phase 1 | |
| Recruiting |
NCT05054543 -
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
|
Phase 3 | |
| Not yet recruiting |
NCT05805072 -
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
|
N/A | |
| Completed |
NCT01319864 -
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
|
Phase 1 | |
| Recruiting |
NCT05428969 -
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04839341 -
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
|
Phase 1 |